BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

BioLineRx Ltd. 

19 Hartum Street
P.O. Box 45158
Jerusalem 91450      Israel
Phone: 972-2-548-9100 Fax: 972-2-548-9101


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
BioLineRx Ltd. Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform 12/12/2014 9:04:04 AM
BioLineRx Ltd. Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at American Society of Hematology Conference 12/8/2014 10:52:11 AM
BioLineRx Ltd. Reports Third Quarter 2014 Financial Results 11/10/2014 10:12:57 AM
BioLineRx Ltd. Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment 11/5/2014 9:35:52 AM
BioLineRx Ltd. Files Protocol Amendment To Phase 2 Study For AML Treatment Based On Encouraging Efficacy And Strong Safety Profile 11/3/2014 10:54:36 AM
BioLineRx Ltd. To Report Third Quarter 2014 Results On November 10, 2014 11/3/2014 10:04:30 AM
BioLineRx Ltd. Reports Publication In Peer Review Journal Of Results From Previous Phase 1/2 Trial For BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction 10/31/2014 9:15:26 AM
BioLineRx Ltd. Presents Positive Preclinical Results In Treatment For AML Patients With FLT3 Mutations 9/17/2014 9:36:05 AM
BioLineRx Ltd. Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment 9/3/2014 10:50:33 AM
BioLineRx Ltd. To Present At The 16th Annual Rodman & Renshaw Global Investment Conference In New York 9/2/2014 11:06:14 AM
12345678910...